# BUYER MEETING PACK — P-02

**Package:** P-02 — Valve that adapts opening profile to ICP trends, reducing pressure excursions
**Date:** 2026-08-26T06:03:14.655173+00:00
**Transfer Posture:** TECHNICAL_DILIGENCE_REQUIRED

---

## PAGE 1: Executive Opportunity

P-02 — Valve that adapts opening profile to ICP trends, reducing pressure excursions. A computationally specified P-02 concept plus a preregistered decisive experiment — not a validated technology. Current evidence: T1. Transfer posture: TECHNICAL_DILIGENCE_REQUIRED. Recommended transaction: SPONSORED_VALIDATION ($10-20K bench). Validation cost: $10-20K.

**Strategic Buyer:** Codman Hakim (adjustable valve manufacturer), Sophysa

**Why This Company Should Care:**
47.3% modeled ICP reduction. If it survives hardware validation, it is a next-generation adjustable valve.

**Recommended Transaction:** SPONSORED_VALIDATION ($10-20K bench)

**Validation Investment:** $10-20K (6-12 months to T2)

---

## PAGE 2: Evidence and Uncertainty

**Current Evidence Level:** T1
**Physical Validation:** NONE

### What Is Demonstrated
- MODELLED: 2 claims
- COMPUTATIONALLY_SUPPORTED: 0 claims
- OBSERVED: 0 claims

### What Is NOT Proven
- NO_FAILURES_TESTED_YET — all evidence is MODELLED. Buyer should treat all claims as untested hypotheses until decisive experiment is commissioned.

### Strongest Alternative
Fixed-pressure programmable valve (Medtronic Strata) — no adaptation

### Remaining Decisive Uncertainty
Whether 47.3% reduction survives real hardware valve dynamics

---

## PAGE 3: Development Roadmap

### Validation Experiment
External model reproduction: independent CFD lab reproduces the 47.3% ICP excursion reduction using a different solver (e.g., ANSYS Fluent or OpenFOAM). Compare results within frozen tolerance.

**Cost:** $10-20K
**Timeline:** 6-12 months to T2
**Pass:** Independent solver reproduces ICP reduction within 20% of modeled 47.3% (i.e., 37.8% to 56.8%)
**Fail:** Independent solver shows <20% reduction or disagrees by >50%

### Development Path
1. **Phase 1 — Bench Validation:** $10-20K (valve prototype + mock CSF) — Medium — valve dynamics
2. **Phase 2 — Prototype:** If Phase 1 passes
3. **Phase 3 — Relevant Environment:** Clinical/cadaver/animal testing
4. **Phase 4 — Regulatory:** 510(k) — valve component
5. **Phase 5 — Commercial Deployment**

### Manufacturing Complexity
Medium — adaptive valve mechanism

---

## PAGE 4: Deal Options

**Recommended Transaction:** SPONSORED_VALIDATION ($10-20K bench)

### Available Options
- sponsored_validation
- option
- exclusive_license

### Strategic Value
Next-gen adaptive valve

### Technology Gap Filled
Fixed-pressure valves cannot adapt to ICP trends

### Incumbent Weakness
Existing adjustable valves require manual clinician intervention

### Buyer Synergies
Extends adjustable valve product line

### Ownership Status
UNVERIFIED — buyer counsel must perform IP diligence

### Regulatory Status
Preliminary hypothesis — buyer regulatory counsel must confirm. See full dossier for details.

---

## PAGE 5: Technical Appendix Reference

**Full Dossier:** `R348/premium_portfolio/TIER_*/NN_P-02/07_PREMIUM_DOSSIER.json`
**Evidence Ledger:** `R348/premium_portfolio/TIER_*/NN_P-02/` → section 07_evidence_validation_ledger
**Experiment Protocol:** `R348/premium_portfolio/TIER_*/NN_P-02/` → section 11_development_experiment_plan
**Risk Register:** `R348/premium_portfolio/TIER_*/NN_P-02/` → section 08_technical_readiness_risk
**Competitive Analysis:** `R348/premium_portfolio/TIER_*/NN_P-02/` → section 06_competitive_alternatives

**T2 Validation Contract:** `R349/validation_contracts/P-02_T2_VALIDATION_CONTRACT.json` (if T1 climber)

**BUYER_ACTION_ID:** P02-EXP-001

---

*This meeting pack is designed for a 30-minute buyer meeting. Pages 1-2 for the executive. Pages 3-4 for the deal team. Page 5 for the technical diligence team.*
